Biomarin Pharmaceutical (BMRN) Revenue (2009 - 2026)

Biomarin Pharmaceutical has disclosed Revenue across 18 years of filings, most recently posting $766.2 million for Q1 2026.

• Quarterly Revenue rose 2.83% year-over-year to $766.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 billion (up 9.9% YoY) and the FY2025 annual result came in at $3.2 billion, up 12.87% from the prior year.
• Revenue retreated to $766.2 million in Q1 2026, from $874.6 million in the prior quarter.
• Over five years, Revenue peaked at $874.6 million in Q4 2025 and troughed at $505.3 million in Q3 2022.
• A 5-year average of $668.0 million and a median of $648.8 million in 2024 frame the typical range for Revenue.
• Annual changes were most pronounced in 2024 — Revenue rose 28.28% — and 2026, when it rose 2.83%.
• Tracing BMRN's Revenue over 5 years: stood at $537.5 million in 2022, then advanced by 20.22% to $646.2 million in 2023, then rose by 15.65% to $747.3 million in 2024, then grew by 17.03% to $874.6 million in 2025, then retreated by 12.39% to $766.2 million in 2026.
• Business Quant data shows BMRN's Revenue at $766.2 million in Q1 2026, $874.6 million in Q4 2025, and $776.1 million in Q3 2025.